

## DAFTAR PUSTAKA

Aartsma-Rus, A. *et al.* (2006) ‘Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule’, *Muscle and Nerve*, 34(2), pp. 135–144. doi: 10.1002/mus.20586.

Aartsma-Rus, A. *et al.* (2019) ‘Evidence-Based Consensus and Systematic Review on Reducing the Time to Diagnosis of Duchenne Muscular Dystrophy’, *Journal of Pediatrics*. Elsevier Inc., 204, pp. 305-313.e14. doi: 10.1016/j.jpeds.2018.10.043.

Aartsma-Rus, A., Ginjaar, I. B. and Bushby, K. (2016) ‘The importance of genetic diagnosis for Duchenne muscular dystrophy’, *Journal of Medical Genetics*, 53(3), pp. 145–151. doi: 10.1136/jmedgenet-2015-103387.

Benchaouir, R. and Goyenville, A. (2019) ‘AAV-Mediated Exon Skipping for Duchenne Muscular Dystrophy’, *Muscle Gene Therapy*, pp. 355–370. doi: 10.1007/978-3-030-03095-7\_20.

Bendixen, R. M. *et al.* (2012) ‘Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health’, *Health and Quality of Life Outcomes*, 10, pp. 1–9. doi: 10.1186/1477-7525-10-43.

Birnkrant, D. J. *et al.* (2018) ‘Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and

gastrointestinal and nutritional management’, *The Lancet Neurology*. Elsevier Ltd, 17(3), pp. 251–267. doi: 10.1016/S1474-4422(18)30024-3.

Blake, D. J. *et al.* (2002) ‘Function and genetics of dystrophin and dystrophin-related proteins in muscle’, *Physiological Reviews*, 82(2), pp. 291–329. doi: 10.1152/physrev.00028.2001.

Brooke, M. H. *et al.* (1989) ‘Duchenne muscular dystrophy: Patterns of clinical progression and effects of supportive therapy’, *Neurology*, 39(4), pp. 475–481. doi: 10.1212/wnl.39.4.475.

Brunherotti, M. A. *et al.* (2007) ‘Correlations of Egen Klassifikation and Barthel Index scores with pulmonary function parameters in Duchenne muscular dystrophy’, *Heart and Lung: Journal of Acute and Critical Care*, 36(2), pp. 132–139. doi: 10.1016/j.hrtlng.2006.07.006.

Bushby, K. *et al.* (2010a) ‘Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management’, *The Lancet Neurology*. Elsevier Ltd, 9(1), pp. 77–93. doi: 10.1016/S1474-4422(09)70271-6.

Bushby, K. *et al.* (2010b) ‘Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care’, *The Lancet Neurology*. Elsevier Ltd, 9(2), pp. 177–189. doi: 10.1016/S1474-4422(09)70272-8.

Carsana, A. *et al.* (2005) 'Analysis of Dystrophin Gene Deletions Indicates that the Hinge III Region of the Protein Correlates with Disease Severity', *Annals of Human Genetics*, 69(3), pp. 253–259. doi: 10.1046/j.1529-8817.2005.00160.x.

Carter, J. C. *et al.* (2018) 'Muscular Dystrophies', *Clinics in Chest Medicine*. Elsevier Inc, 39(2), pp. 377–389. doi: 10.1016/j.ccm.2018.01.004.

Chang, R. F. and Mubarak, S. J. (2012) 'Pathomechanics of gowers' sign: A video analysis of a spectrum of gowers' maneuvers', *Clinical Orthopaedics and Related Research*, 470(7), pp. 1987–1991. doi: 10.1007/s11999-011-2210-6.

Ciafaloni, E. *et al.* (2009) 'Delayed Diagnosis in Duchenne Muscular Dystrophy: Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)', *Journal of Pediatrics*. Mosby, Inc., 155(3), pp. 380–385. doi: 10.1016/j.jpeds.2009.02.007.

Collin, C. *et al.* (1988) 'The barthel ADL index: A reliability study', *Disability and Rehabilitation*, 10(2), pp. 61–63. doi: 10.3109/09638288809164103.

Crone, M. and Mah, J. K. (2018) 'Current and Emerging Therapies for Duchenne Muscular Dystrophy', *Current Treatment Options in Neurology*, 20(8), pp. 1795–1807. doi: 10.1007/s11940-018-0513-6.

Dalkilic, I. and Kunkel, L. M. (2003) 'Muscular dystrophies: Genes to pathogenesis', *Current Opinion in Genetics and Development*, 13(3), pp. 231–238. doi:

10.1016/S0959-437X(03)00048-0.

Darras, B. T., Urion, D. K. and Ghosh, P. S. (2019) 'Dystrophinopathies Summary Genetic counseling GeneReview Scope', pp. 1–35.

Dwianingsih, E. K. *et al.* (2019) 'Paediatrica Indonesiana', 59(5), pp. 257–264.

Emery, A. E. H., Muntoni, F. and Quinlivan, R. (2015) *DUCHENNE MUSCULAR DYSTROPHY*. 4th editio. Oxford: Oxford University Press.

Falzarano, M. S. *et al.* (2015) 'Duchenne muscular dystrophy: From diagnosis to therapy', *Molecules*, 20(10), pp. 18168–18184. doi: 10.3390/molecules201018168.

G, G. (2015) 'The Barthel Index: Italian Translation, Adaptation and Validation', *International Journal of Neurology and Neurotherapy*, 2(1). doi: 10.23937/2378-3001/2/1/1028.

Gao, Q. Q. and McNally, E. M. (2015) 'The dystrophin complex: Structure, function, and implications for therapy', *Comprehensive Physiology*, 5(3), pp. 1223–1239. doi: 10.1002/cphy.c140048.

Giannakopoulos, S. *et al.* (2015) 'Identification of Serum Biomarkers for Duchenne Muscular Dystrophy (P2.239)', *Neurology*, 84(14 Supplement), p. P2.239. Available at: [http://n.neurology.org/content/84/14\\_Supplement/P2.239.abstract](http://n.neurology.org/content/84/14_Supplement/P2.239.abstract).

Granger, C. V *et al.* (1989) 'The stroke rehabilitation outcome study: Part II. Relative merits of the total Barthel index score and a four-item subscore in predicting patient

outcomes.’, *Archives of physical medicine and rehabilitation*, 70(2), pp. 100–3.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2916925>.

Hoffman, E. P. *et al.* (1987) ‘Conservation of the Duchenne muscular dystrophy gene in mice and humans’, *Science*, 238(4825), pp. 347–350. doi: 10.1126/science.3659917.

Hong, I. *et al.* (2017) ‘Application of the Korean version of the Modified Barthel Index: Development of a keyform for use in clinical practice’, *Hong Kong Journal of Occupational Therapy*. Elsevier Ltd, 29, pp. 39–46. doi: 10.1016/j.hkjot.2017.06.001.

Jacelon, C. S. (1986) ‘The Barthel Index and Other Indices of Functional Ability’, *Rehabilitation Nursing*, 11(4), pp. 9–11. doi: 10.1002/j.2048-7940.1986.tb00995.x.

Kate Stone *et al.* (2007) *Occupational Therapy and Duchenne Muscular Dystrophy*, John Wiley & Sons.

Kemper, A. R. and Wake, M. A. (2007) ‘Duchenne muscular dystrophy: Issues in expanding newborn screening’, *Current Opinion in Pediatrics*, 19(6), pp. 700–704. doi: 10.1097/MOP.0b013e3282f19f65.

Kerr, R. *et al.* (2013) ‘Genetic testing for Duchenne/Becker muscular dystrophy in Johannesburg, South Africa’, *South African Medical Journal*, 103(SUPPL. 1), pp. 999–1004. doi: 10.7196/SAMJ.7274.

Kliegman, R. M. *et al.* (2016) *Nelson Textbook of Pediatrics*, Journal of Chemical

*Information and Modeling*. Philadelphia: Elsevier. doi:  
10.1017/CBO9781107415324.004.

Koenig, M. *et al.* (1987) 'Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals', *Cell*, 50(3), pp. 509–517. doi: 10.1016/0092-8674(87)90504-6.

Kornegay, J. N. *et al.* (2012) 'The Paradox of Muscle Hypertrophy in Muscular Dystrophy', *Physical Medicine and Rehabilitation Clinics of North America*, 23(1), pp. 149–172. doi: 10.1016/j.pmr.2011.11.014.

Leung, D. G. *et al.* (2011) 'Report on the second endocrine aspects of duchenne muscular dystrophy conference December 1-2, 2010, Baltimore, Maryland, USA', *Neuromuscular Disorders*. Elsevier B.V., 21(8), pp. 594–601. doi: 10.1016/j.nmd.2011.04.008.

Lovering, R. M., Porter, N. C. and Block, R. J. (2005) 'The Muscular Dystrophies: From Genes to Therapies', *Physical Therapy*, 85(12), pp. 1372–1388. doi: 10.1016/b978-1-4831-8407-4.50152-8.

Lue, Y. J. *et al.* (2009) 'Measurement of the Functional Status of Patients with Different Types of Muscular Dystrophy', *Kaohsiung Journal of Medical Sciences*. Elsevier, 25(6), pp. 325–333. doi: 10.1016/S1607-551X(09)70523-6.

Lue YJ *et al.* (1993) ‘Investigation of activity of daily living performance in patients with Duchenne muscular dystrophy’, *Gaoxiong Yi Xue Ke Xue Za Zhi*, 9(6), pp. 351–360. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/8340959>.

Mah, J. K. *et al.* (2014) ‘A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy’, *Neuromuscular Disorders*. Elsevier B.V., 24(6), pp. 482–491. doi: 10.1016/j.nmd.2014.03.008.

MAHONEY, F. I. and BARTHEL, D. W. (1965) ‘Functional Evaluation: the Barthel Index.’, *Maryland state medical journal*, 14(9), pp. 61–65.

McDowell, I. (2009) *Measuring Health: A guide to rating scales and questionnaires*, *Measuring Health: A Guide to Rating Scales and Questionnaires*. doi: 10.1093/acprof:oso/9780195165678.001.0001.

Melis, M. A. *et al.* (1998) ‘Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families’, *European Journal of Paediatric Neurology*, 2(5), pp. 255–261. doi: 10.1016/S1090-3798(98)80039-1.

Meyers, T. A. and Townsend, D. (2019) ‘Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy’, *International Journal of Molecular Sciences*, 20(17), p. 4098. doi: 10.3390/ijms20174098.

Monaco, A. P. *et al.* (1988) ‘An explanation for the phenotypic differences between

patients bearing partial deletions of the DMD locus', *Genomics*, 2(1), pp. 90–95. doi: 10.1016/0888-7543(88)90113-9.

Muntoni, F., Torelli, S. and Ferlini, A. (2003) 'Dystrophin and mutations: One gene, several proteins, multiple phenotypes', *Lancet Neurology*, 2(12), pp. 731–740. doi: 10.1016/S1474-4422(03)00585-4.

Nair, K. P. S. *et al.* (2001) 'Disabilities in children with Duchenne muscular dystrophy: A profile', *Journal of Rehabilitation Medicine*, 33(4), pp. 147–149. doi: 10.1080/165019701750300591.

Nakamura, A. *et al.* (2008) 'Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene', *Journal of Clinical Neuroscience*, 15(7), pp. 757–763. doi: 10.1016/j.jocn.2006.12.012.

Niks, E. H. and Aartsma-Rus, A. (2017) 'Exon skipping: a first in class strategy for Duchenne muscular dystrophy', *Expert Opinion on Biological Therapy*. Taylor & Francis, 17(2), pp. 225–236. doi: 10.1080/14712598.2017.1271872.

Opstal, S. L. S. H. Van *et al.* (2014) 'Health-related quality of life and its relation to disease severity in boys with duchenne muscular dystrophy: Satisfied boys, worrying parents - A case-control study', *Journal of Child Neurology*, 29(11), pp. 1486–1495. doi: 10.1177/0883073813506490.

Rosales, X. Q. *et al.* (2015) 'Fidelity of Gamma-Glutamyl Transferase', pp. 21–24.

Ruiten, H. J. A. Van *et al.* (2014) 'Improving recognition of Duchenne muscular dystrophy: a retrospective case note review', pp. 1–5. doi: 10.1136/archdischild-2014-306366.

Ryder, S. *et al.* (2017) 'The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An evidence review', *Orphanet Journal of Rare Diseases*. *Orphanet Journal of Rare Diseases*, 12(1), pp. 1–21. doi: 10.1186/s13023-017-0631-3.

Schulc, E. *et al.* (2015) 'Is the Barthel Index an Adequate Assessment Tool for Identifying a Risk Group in Elderly People Living at Home?', *International Journal of Nursing & Clinical Practices*, 2(1). doi: 10.15344/2394-4978/2015/140.

Taglia, A. *et al.* (2015) 'Clinical features of patients with dystrophinopathy sharing the 45-55 exon deletion of DMD gene', *Acta Myologica*, 34(1), pp. 9–13.

Thong, M. K., Bazlin, R. I. R. and Wong, K. T. (2005) 'Diagnosis and management of Duchenne muscular dystrophy in a developing country over a 10-year period', *Developmental Medicine and Child Neurology*, 47(7), pp. 474–477. doi: 10.1017/S0012162205000915.

Tzeng, A. C. and Bach, J. R. (2000) 'Prevention of pulmonary morbidity for patients with neuromuscular disease', *Chest*. The American College of Chest Physicians, 118(5), pp. 1390–1396. doi: 10.1378/chest.118.5.1390.

Uchikawa, K. *et al.* (2004) 'Functional status and muscle strength in people with Duchenne muscular dystrophy living in the community', *Journal of Rehabilitation Medicine*, 36(3), pp. 124–129. doi: 10.1080/16501970410023461.

Uttley, L. *et al.* (2018) 'A review of quality of life themes in Duchenne muscular dystrophy for patients and carers', *Health and Quality of Life Outcomes*. Health and Quality of Life Outcomes, 16(1), pp. 1–16. doi: 10.1186/s12955-018-1062-0.

Vengalil, S. *et al.* (2017) 'Duchenne muscular dystrophy and becker muscular dystrophy confirmed by multiplex ligation-dependent probe amplification: Genotype-phenotype correlation in a large cohort', *Journal of Clinical Neurology (Korea)*. Korean Neurological Association, 13(1), pp. 91–97. doi: 10.3988/jcn.2017.13.1.91.

Verma, S., Anziska, Y. and Cracco, J. (2010) 'Review of duchenne muscular dystrophy (Dmd) for the pediatricians in the community', *Clinical Pediatrics*, 49(11), pp. 1011–1017. doi: 10.1177/0009922810378738.

Wang, X. *et al.* (2008) 'Similarity of DMD gene deletion and duplication in the Chinese patients compared to global populations', *Behavioral and Brain Functions*, 4, pp. 1–9. doi: 10.1186/1744-9081-4-20.

White, S. J. *et al.* (2006) 'Duplications in theDMD gene', *Human Mutation*, 27(9), pp. 938–945. doi: 10.1002/humu.20367.

Wood, M. J. A., Gait, M. J. and Yin, H. (2010) 'RNA-targeted splice-correction

therapy for neuromuscular disease', *Brain*, 133(4), pp. 957–972. doi:

10.1093/brain/awq002.